Analysts Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) PT at $48.00

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $48.00.

NAMS has been the topic of several research reports. Needham & Company LLC lifted their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Finally, Guggenheim boosted their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. The trade was a 71.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61. Following the sale, the insider directly owned 69,302 shares in the company, valued at $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,168,286 shares of company stock valued at $38,211,967 over the last ninety days. 12.74% of the stock is owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the period. KBC Group NV purchased a new position in shares of NewAmsterdam Pharma during the first quarter valued at approximately $37,000. Navalign LLC purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $46,000. Finally, Wolverine Asset Management LLC purchased a new position in shares of NewAmsterdam Pharma during the third quarter valued at approximately $69,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $35.44 on Friday. The company has a market capitalization of $4.14 billion, a PE ratio of -19.80 and a beta of 0.02. The business’s fifty day moving average is $32.33 and its 200 day moving average is $34.32. NewAmsterdam Pharma has a fifty-two week low of $16.78 and a fifty-two week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The firm had revenue of $3.04 million during the quarter. On average, sell-side analysts forecast that NewAmsterdam Pharma will post -1.76 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.